Treatment-Resistant Depression

Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

New study shows lumateperone (Caplyta) significantly improves symptoms in major depressive disorder with anxious distress, offering hope for treatment-resistant patients.

Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.